Standard BioTools Net Tangible Assets

Standard BioTools (LAB) currently reports a net tangible assets of $540M as of June 2026. That compares with $420M in the prior-year period — up 27.2% year over year. Use the charts on this page to explore Standard BioTools's net tangible assets history and peer comparisons.

Standard BioTools's net tangible assets increased from $420M to $540M — a 27.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Standard BioTools reported $540M in net tangible assets as of June 2026. That compares with $420M in the prior-year period — up 27.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $540M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Standard BioTools, and consider following LAB for alerts when major investors trade the stock.

Standard BioTools is classified in the Healthcare sector. On net tangible assets, it currently shows $540M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LAB with unrelated industries.